Research programme: Fabry's disease therapeutics - Evotec AG/Shire

Drug Profile

Research programme: Fabry's disease therapeutics - Evotec AG/Shire

Latest Information Update: 17 Oct 2014

Price : $50

At a glance

  • Originator Evotec AG; Shire
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Fabry's disease

Most Recent Events

  • 12 Aug 2014 Early research in Fabry's disease in Germany (unspecified route) before August 2014
  • 12 Aug 2014 Early research in Fabry's disease in Ireland (unspecified route) before August 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top